BioLineRx initiated with a Buy at JonesResearch

JonesResearch initiated coverage of BioLineRx with a Buy rating and $2 price target. BioLineRx is a commercial stage biopharmaceutical company developing and commercializing therapies for the treatment of cancer and rare diseases, the analyst tells investors in a research note. The firm believes the combination of :differentiated clinical data and compelling economic benefit arguments” will drive increasing Aphexda use in MM and facilitate its approval and uptake in sickle cell disease.